AVEO Pharmaceuticals EBIT

The latest EBIT for AVEO is $-24M as of September 2022. That compares with $-56M in the prior-year period — up 56.3% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside AVEO Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, AVEO's EBIT moved from $-56M to $-24M — a 56.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AVEO Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, AVEO currently prints $-24M for EBIT, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at AVEO Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-24M for AVEO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting AVEO's EBIT ($-24M), review year-over-year change from $-56M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.